Skip to content
Catalyst

knowcompoundsN(5)-ethyl-L-glutamine

Specimen compound organic compoundPlate I

L-theanine

Nested hairline contours trace the electron density of one computed shape of N(5)-ethyl-L-glutamine, teal at the edge warming to amber over the atoms.
fig. 1L-theanine · electron density · PubChem CID 439378, computed 3D conformer
Formula
C7H14N2O3
Molar mass
174.2 g/mol
PubChem CID
439378
InChIKey
DATAGRPVKZEWHA-YFKPBYRVSA-N

↓ lowered 4 findings in 4 endpoints · – no difference found 1 in 1

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
0
Limited
1
Very limited
4
Insufficient
0

How to read these marks

Fig. 2 L-theanine CHEBI:17394 5 endpoints 5 findings
×1.60
Labels
CompoundInspector

L-theanine

Most findings

  • Insomnia Severity Index (ISI) total score×1
  • Isometric peak force×1
  • PANSS general psychopathology subscale score×1
  • PANSS positive subscale score×1
  • Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score×1

5 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. Isometric peak force
  2. Insomnia Severity Index (ISI) total score
  3. PANSS general psychopathology subscale score
  4. PANSS positive subscale score
  5. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score
fig. 3 · 5 endpoints · 5 findingsno endpoint contested

02 · findings

What L-theanine moved, and by how much

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction
Strength, at least

5 shown

  1. Isometric peak forceMoved: lowersEvidence: LimitedPaper: PMID 416687202025
    Who
    20 young competitive athletes (12 male, 8 female), four-condition randomized double-blind crossover; theanine alone versus mannitol placebo; leg and back isometric strength by dynamometer
    Dose studied
    200 mg L-theanine capsules, single dose 60 min before testing

    In contrast, L-theanine was associated with lower leg and back strength values compared with placebo, indicating a negative effect on maximal isometric force production.”

    Quoted verbatim from Acute effects of combined and isolated caffeine and theanine supplementation on physical and cognitive performance in competitive athletes: a randomized, double-blind, placebo-controlled crossover study.crossoverPermalink
  2. Insomnia Severity Index (ISI) total scoreMoved: no difference foundEvidence: Very limitedPaper: PMID 305800812019
    Who
    Adults with DSM-5 generalized anxiety disorder, all on stable antidepressant treatment in both arms
    Dose studied
    adjunctive L-theanine 450-900 mg

    Results revealed that adjunctive L-theanine did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35).”

    Quoted verbatim from L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial.RCT · 8 weeksPermalink
  3. PANSS positive subscale scoreMoved: lowersEvidence: Very limitedPaper: PMID 212085862011
    Who
    Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model
    Dose studied
    L-theanine 400 mg/d added to ongoing antipsychotic

    Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).”

    Quoted verbatim from L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.RCT · 8 weeksPermalink
  4. PANSS general psychopathology subscale scoreMoved: lowersEvidence: Very limitedPaper: PMID 212085862011
    Who
    Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model
    Dose studied
    L-theanine 400 mg/d added to ongoing antipsychotic

    Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).”

    Quoted verbatim from L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.RCT · 8 weeksPermalink
  5. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total scoreMoved: lowersEvidence: Very limitedPaper: PMID 371695152023
    Who
    Adults 18-60 with DSM-5 OCD and baseline Y-BOCS above 21; fluvoxamine given to both arms as background (100 mg daily, 200 mg daily after week 5); 10-week parallel-group trial; primary outcome was Y-BOCS total decrease from baseline; result recorded is the week-10 contrast
    Dose studied
    L-theanine 100 mg twice daily, oral, added to fluvoxamine

    Also, total Y-BOCS scores were lower in L-theanine compared to placebo group at week 5 (P = 0.039, Cohen's d = 0.60) and 10 (P = 0.008, Cohen's d = 0.80).”

    Quoted verbatim from L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.RCT · 2 monthsPermalink

No dose is advised.

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · identity

Structure

fig. 4L-theanine · 2D structure · ChEBI’s SMILES
Charge
0
SMILES
CCNC(=O)CC[C@H](N)C(=O)O

04 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reactions · Rhea
2reactions

05 · on the label · 2,090 products

Labelled products

Source: NIH DSLD · Ingredient: N(5)-ethyl-L-glutamine · 2,090 products · Declared amount per serving (the first 1,000 shown): 1–1,000 mg

747 labels of the first 1,000 shown state an amount253 do not

  • 1 BodyBrain Support100 mgper 3 capsulesDSLD:257246
  • 1st PhormRoyal XXI Kingamount not statedper 1 capsuleDSLD:211507
  • 1st PhormRoyal XXI Queenamount not statedper 1 capsuleDSLD:211508
  • 21st CenturyBrilliant Brain100 mgper 2 tabletsDSLD:205530
  • 4 OrganicsAppetite Awayamount not statedper 1 capsuleDSLD:26218
  • 4 OrganicsAppetite Awayamount not statedper 1 capsuleDSLD:268146
  • 4 OrganicsAppetite Awayamount not statedper 1 capsuleDSLD:268147
  • 4 OrganicsJumpstart Boost Formula EXamount not statedper 1 capsuleDSLD:268152
  • 4 OrganicsJumpstart Boost Formula EXamount not statedper 1 capsuleDSLD:268153
  • 4 OrganicsSerene Relaxation/Sleep Supportamount not statedper 2 capsulesDSLD:268158
  • 4 OrganicsSerene Relaxation/Sleep Supportamount not statedper 2 capsulesDSLD:268159
  • 8WeeksOutIntellect250 mgper 3 capsulesDSLD:228495
Show the remaining 2,078Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

06 · the record

Sources

102

papers screened for L-theanine

admitted
6
read and discarded
41
not read yet
55

The screening record, every paper and why

Sources cited

4 papers · 5 findings

2 admitted at screening, no finding yet

Show every paper citedHide the papers cited
753Endpoints measured, not recorded as findingsEvery row, on one page
47Papers indexed under L-theanine